HIV-1C proviral DNA for detection of drug resistance mutations

Kahsay Huruy¹, Andargachew Mulu²*, Uwe Gerd Liebert³, Maier Melanie³

¹ Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, University of Gondar, Gondar, Ethiopia, ² Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia, ³ Institute of Virology, Leipzig University, Leipzig, Germany

* andargachewmulu@yahoo.com

Abstract

Background

Using HIV proviral DNA as a template may be suitable for initial detection of transmitted drug resistance mutations (TDRMs) as it is easy to handle and less expensive compared to RNA. However, existing literatures which are mainly focused on HIV-1B subtypes DNA extracted from PBMCs revealed controversial findings ranging from the detection of significantly lower or higher mutations in proviral DNA compared to historic viral RNA. Thus, to verify whether viral RNA or proviral DNA has improved sensitivity in detecting transmitted genotypic drug resistance mutations paired viral RNA and proviral DNA (which is directly extracted from stored whole blood) samples were tested from Ethiopian antiretroviral naive HIV-1C infected subjects.

Methods

In the present comparative study the frequency of TDR mutations was assessed in paired samples of viral RNA and proviral DNA (extracted directly from stored whole blood) of HIV-1C infected treatment naïve patients and interpreted using the 2009 WHO drug resistance surveillance mutation lists, Stanford University drug resistance data base and International Antiviral Society-USA mutation lists.

Results

High agreement in rate of TDR between the two compartments was observed using the WHO mutation lists. While mutations G190A and E138A were concurrently found in both compartments, others such as G73S on PR and A62V, M184I, M230I on RT were identified in proviral DNA only. All signature mutations seen in viral RNA were not missed in proviral DNA.

Conclusions

The concordance of major genotype drug resistance mutation between RNA and proviral DNA in treatment naïve patients suggests that proviral DNA might be an alternative approaches for an initial assessment of drug resistance prior to initiation of antiretroviral
therapy using the WHO mutations lists in resource-limited countries. However, the clinical importance of TDRMs observed only in proviral DNA in terms of being a risk factor for virologic failure and whether they limit future treatment options needs additional investigation using more sensitive sequencing approaches such as Next Generation Sequencing (NGS).

Background

Since the introduction of antiretroviral therapy (ART), the relative rates of morbidity and mortality from acquired immunodeficiency syndrome have been reduced significantly [1]. However, the clinical benefits of ART are jeopardized by the emergence of drug-resistant HIV-1 strains [2, 3]. The currently available ART is directed against virus-specific enzymes as well as the processes of attachment and entry into cells and are not curative nor eradicate HIV infection, as latent infection is established through the integration of double-stranded proviral DNA into the host cell which is essential during HIV life cycle [4]. The proviral DNA archives viral variants and preserves them until transcription and translation is initiated in these cells again. These cells, at least temporarily not producing virus, represent a barrier to viral eradication and it is inherently difficult to specifically target and remove such cells [5]. Accordingly, proviral DNA has been investigated as an additional source of information on HIV-1 resistance analysis [6–11]. Simultaneous analysis of viral RNA and proviral DNA apparently increases the sensitivity of TDR detection and testing of proviral DNA may also be important for monitoring treatment outcomes [12]. However, existing literatures which are mainly focused on HIV-1B subtypes revealed controversial findings ranging from the detection of significantly lower [6, 8] or higher [9, 11] mutations in proviral DNA compared to historic viral RNA to a high level of genotype concordance between RNA and proviral DNA in newly diagnosed viremic patients [13–15] and in a viremic patients under ART [13, 15]. Moreover, most of the above comparative studies were conducted on DNA extracted from PBMCs which is more labor intensive and expensive to prepare and requires at least -70°C cold storage which is not available in most laboratories of the developing countries.

Thus, to verify whether viral RNA or proviral DNA has improved sensitivity in detecting transmitted genotypic drug resistance mutations paired viral RNA and proviral DNA (which is directly extracted from stored whole blood) samples were tested from antiretroviral naive HIV-1C infected subjects from Ethiopian where HIV-1 transmitted drug resistance is increasing [16–21].

Materials and methods

Four ml of whole blood was collected in EDTA-containing tubes from 41 ART naïve HIV-1C infected patients from Northwest Ethiopia (Gondar University and Metema Hospitals) during January to March 2010. For preservation of cells, blood samples were immediately mixed with ethylene and propylene glycol (EPG, Sigma Chemical Co., Gaithersburg, Md, USA; final EPG concentration 20%) [22] and stored at -20 °C. CD4+ T-cell count was performed on fresh whole blood by flow cytometry (FACScount system, Becton Dickinson, San Jose, CA, USA) following the manufacturer’s specifications. Details of patient’s recruitment and management has been described elsewhere [20].

Extraction of plasma RNA, HIV-1 viral load determination and HIV-1 viral genome amplification and sequencing of protease codons 1–99 and reverse transcriptase codons 1–331 was done as described previously [17]. DNA was manually extracted from the cellular fraction.
according to published protocol with minor modifications [23]. Briefly, PBS (phosphate buffered saline) containing 0.1% NP-40 was added at a ratio of 1:5 to 1 ml of whole blood supplemented with EPG and centrifuged at 3,000 x g for 5 min. The pellet was re-suspended in PBS (1 ml containing 5% SDS) and incubated at 37 °C for 30 min. Thereafter, equal volume of lyses buffer (8 M urea, 0.3 M NaCl, 10 mM EDTA, 10 mMTris-HCl pH 7.5) was added, followed by further incubation at 37 °C for 30 min. Total DNA was manually extracted by phase extraction using organic solvent, followed by ethanol precipitation.

Amplification of HIV-1 proviral DNA was done using the same protocol as for viral RNA [17] but omitting the RT step. PCR final products for viral RNA and proviral DNA were purified using Wizard SV Gel and PCR Clean-up kit (Promega, Madison, WI, USA). The purified PCR products were sequenced using the fluorescent dideoxy-terminator method and the ABI Prism 3100 genetic analyser (Applied Biosystem, Foster City, CA, USA). FASTA files were analysed using Stanford University HIV-1 Sequence Database (http://hivdb.stanford.edu), which contains a computer assisted interpretation of mutational profiles providing five levels of inferred drug resistance. All except the fully susceptible HIV-1 sequences were considered as resistant in the analysis of the present study. Each sequence from both compartments was also analysed using WHO mutation lists (http://cpr.stanford.edu.cpr.cgi) and the updated 2017 International Antiviral Society (IAS) mutation lists [24]. All sequences obtained from both, viral RNA and proviral DNA, were confirmed using the Rega HIV-1 subtyping tool, version 2.0 (http://www.bioafrica.net/subtypetool). Phylogenetic tree was constructed by the neighbour-joining method using data generated from the pol region (RT and PR genes) of all viral RNA and proviral DNA sequences. The reliability of the branching orders was assessed using the bootstrap approach with MEGA version 5 [25]. Seventeen reference strains, 9 representing HIV-1C and 8 representing non-B subtypes were included for comparison. The nucleotide sequences were deposited at the National Centre for Biotechnology Information (NCBI), USA GenBank (accession numbers KJ807732 to KJ807772 for proviral DNA and KJ807649 to KJ807689 for viral RNA).

Statistical analysis was carried out using SPSS software, version 17.0 (SPSS, Chicago, IL, USA). Mean and standard deviation (SD) were computed for the different variables. A P-value less than 0.05 was considered statistically significant and 95% confidence intervals (CI) were computed by GraphPad Prism software version 5 (San Diego, CA, USA).

**Ethics approval and consent to participate**

All of the protocols using human specimens including written consent were approved by The University of Gondar Ethical Review Committee (RPO 55/258/2001) and written consent was obtained from all of the subjects.

**Results**

The characteristics of the study subjects (n = 41) are summarized in Table 1. Thirty-three were in age group 26–45 years and 24 (58.5%) were men. Only eight patients (19.5%) had more than 200 CD4+ T cells per ml. The mean ± SD of viral load (log_{10} copies/ml) and hemoglobin values (g/dl) of the patients was 4.76 ± 0.60 and 10.98 ± 2.5, respectively. Female gender but not age, baseline CD4 cell count and hemoglobin values was significantly associated with drug resistance [odds ratio 6.22, p = 0.020].

The pol consensus sequences consisting of 1,261 nucleotides were analyzed to assess the similarity between the viral RNA and proviral DNA (Fig 1). For all patients the infecting virus was identified as HIV-1C. The phylogenetic tree reveals a high genetic similarity between viral
RNA and proviral DNA. However, in four paired samples (G7, M31, M42, and M65) RNA and DNA sequences clustered at different branches.

Overall, sequence profiles of both RNA and proviral DNA were concordant in 83% (34/41) of the patients. Thirty patients had wild type genotype in both PR and RT region of the pol genome from both viral RNA and proviral DNA; eleven patients (26.8%, Table 2) had a mutant type from both compartments conferring transmitted drug resistance, of which in four patients mutations were concurrently detected both in RNA and proviral DNA; in two patients mutations were only found in viral RNA (patients ID G043 and G174) and in five patients drug resistance mutations occurred only in proviral DNA (patients ID G020, G168, G269, M072 and M092). Despite differences between the different algorithms, in all algorithms DNA is more sensitive to detect drug resistance mutations and none of the signature mutations found in viral RNA was missed in proviral DNA. High agreement in rate of TDR between HIV RNA and proviral DNA was observed using the WHO drug resistance surveillance mutation lists with coefficient of agreement (Table 3). The prevalence of TDR is summarized in Table 2. The overall rate of TDR to at least one drug class using WHO mutation lists, Stanford University Algorithm database and the IAS mutation lists was 19.5% (8/41 patients, CI 10.0–34.3%), 22.0% (9/41, CI 11.8–36.9%) and 26.8% (11/41; CI 15.6–42.1%), respectively (Table 3). Out of the 5 patients with drug resistant associated mutations in proviral DNA, three had ≥2 APOBEC3G/F signature mutations (M184I and M230I) in reverse transcriptase region with G-to-A mutations. However, since we do not know the role of APOBEC3G/F activity on future virological outcomes (particualrly in HIV-1C isolates), we prefered to count these mutations in the rate of TDR.

Four out of eleven patients (G20, G168, M72 and M92) had two TDR in their proviral DNA representing multi-drug resistance (Table 2). The rest seven patients (17.1%) harboured a virus with one mutation each in viral RNA or proviral DNA or both compartments. The profile of TDR was: in four patients mutations (i.e. G190A, E138A/G) were found concurrently both in viral RNA and proviral DNA, in two patients resistance mutations (M46I and G190E) were detected only in viral RNA, and in five patients archived transmitted drug resistance mutations (M230I, G73S, M184I, M46I, and A62V) in proviral DNA were identified. TDR appeared to be higher in patients with CD4+ cell count < 100 cells/mm$^3$ (72.7%) and in

### Table 1. Baseline characteristics of patients.

| Total number of patients | 41 |
|--------------------------|----|
| Sex                      |    |
| Men                      | 24 (58.5%) |
| Women                    | 17 (41.5%) |
| Age (years)              |    |
| 21–25                    | 5 (12.2%) |
| 26–35                    | 23 (56.1%) |
| 36–45                    | 10 (24.4%) |
| ≥ 46                     | 3 (7.3%) |
| Mean ± SD of hemoglobin (g/dl) | 10.98 ± 2.5 |
| CD4 cell count (cells per mm$^3$) |    |
| < 50                     | 11 (26.8%) |
| 50–99                    | 11 (26.8%) |
| 100–199                  | 11 (26.8%) |
| 200–320                  | 8 (19.5%) |
| Mean ± SD of HIV RNA viral load (log$_{10}$ copies per ml) | 4.76 ± 0.60 |

https://doi.org/10.1371/journal.pone.0205119.t001
patients who were in the age group of 26–35 years (81.8%, Table 2). However, these differences were not statistically significant ($P > 0.05$). TDR to NNRTI was identified in 22.0% (9/41) of patients from both, viral RNA and proviral DNA, and in three patient’s resistance mutations to PIs. NRTIs related mutations M184I and A62V were only found in proviral DNA (Table 2). HIV-1 proviral DNA from sample G168 had two archived transmitted drug resistance mutations (M46I and M230I) the same is true for G020 (G73S and M230I). Please note that, E138A is a polymorphic change depending on subtype and could occur in 0.5% to 5% of viruses from treatment naive patients. However, its presence reduces ETR and RPV susceptibility by about
2-fold and hence the presence of E138A prior to therapy may reduce the antiviral activity of RPV. Thus, E138A is considered as a TDR mutation.

The abundance of polymorphisms (Table 4) at known drug resistance positions were significantly higher in proviral DNA (24.4% (10/41); 95% CI 13.7–29.5%) than in viral RNA (17.1% (7/41); 95% CI, 8.2–31.6%). Polymorphic changes at the drug resistance sites were more frequent in PR region than in the RT region in both compartments where 80% (8/10) and 85.7% (6/7) were identified in plasma RNA and proviral DNA, respectively. Positions V82I (PR) and A98S (RT) were most common polymorphic alterations in both compartments (Table 5).

**Discussion**

In the present study, 83% (34/41) of the patient’s had concordant sequence profile in determining transmitted drug resistance from both RNA and proviral DNA and those major mutations conferring transmitted drug resistance in RNA (the gold-standard template for HIV drug resistance testing as it reflects the virus that is actively reproducing) were also concordantly detected in proviral DNA consistent with recent finding [13] and suggest that proviral DNA could be used as an alternative template for determining transmitted drug resistance particularly in developing countries considering the fact that: i) RNA genotyping requires RNA extraction and storage at least at -70°C which in most cases is not available in developing countries, and ii) the presence of E138A prior to therapy may reduce the antiviral activity of RPV. Thus, E138A is considered as a TDR mutation.

The abundance of polymorphisms (Table 4) at known drug resistance positions were significantly higher in proviral DNA (24.4% (10/41); 95% CI 13.7–29.5%) than in viral RNA (17.1% (7/41); 95% CI, 8.2–31.6%). Polymorphic changes at the drug resistance sites were more frequent in PR region than in the RT region in both compartments where 80% (8/10) and 85.7% (6/7) were identified in plasma RNA and proviral DNA, respectively. Positions V82I (PR) and A98S (RT) were most common polymorphic alterations in both compartments (Table 5).

**Table 2. Characteristics of patients with transmitted drug resistant strains.**

| Code | Age (years) | Gender | CD4⁺ count (cells/mm³) | Viral load (log₁₀ copies/ml) | Drug resistance associated mutations |
|------|-------------|--------|------------------------|-----------------------------|-------------------------------------|
|      |             |        |                        |                             | PI (Viral RNA) | NRTI (Viral RNA) | NNRTI (Viral RNA) | PI (Proviral DNA) | NRTI (Proviral DNA) | NNRTI (Proviral DNA) |
| G014 | 35          | Female | 253                    | 5.65                        | -          | -                | -                | -              | -                | G190A*         |
| G020 | 31          | Female | 104                    | 4.34                        | -          | G73S*           | -                | -              | -                | G190A         |
| G043 | 44          | Female | 62                     | 4.31                        | M46I**     | -                | -                | -              | -                | -              |
| G086 | 55          | Female | 36                     | 4.82                        | -          | -                | -                | -              | -                | E138A*         |
| G168 | 30          | Female | 75                     | 4.92                        | -          | M46I            | -                | -              | -                | E138A         |
| G174 | 30          | Female | 34                     | 4.52                        | -          | -                | -                | -              | -                | M230I         |
| G183 | 27          | Female | 29                     | 4.49                        | -          | -                | -                | -              | -                | G190E*         |
| G269 | 35          | Male   | 20                     | 5.58                        | -          | -                | -                | A62V*          | -                | -              |
| M072 | 26          | Female | 18                     | 4.94                        | -          | -                | -                | M184I***       | -                | M230I         |
| M086 | 28          | Male   | 201                    | 4.11                        | -          | -                | -                | G190A          | G190A           |
| M092 | 30          | Male   | 91                     | 4.41                        | -          | -                | -                | M184I          | -                | M230I         |

PI-protease inhibitor; NRTI-nucleotide reverse transcriptase inhibitor; NNRTI-nucleotide reverse transcriptase inhibitor; (+) no drug resistant mutations detected; (*) mutations found in WHO mutation lists; (**) mutations according to Stanford University drug resistance database; (#) mutations found in IAS lists.

[https://doi.org/10.1371/journal.pone.0205119.t002](https://doi.org/10.1371/journal.pone.0205119.t002)

**Table 3. TDR frequency according to different algorithms.**

| TDR found in | Number of patients (relative frequency) |
|--------------|-----------------------------------------|
|              | WHO | Stanford | IAS |
| Viral RNA    | 4 (9.8%) | 5 (12.2%) | 5 (12.2%) |
| Proviral DNA | 6 (14.6%) | 7 (17.1%) | 9 (22.0%) |
| Overall TDR  | 8 (19.5%) | 9 (22.0%) | 11 (26.8%) |

[https://doi.org/10.1371/journal.pone.0205119.t003](https://doi.org/10.1371/journal.pone.0205119.t003)
countries; ii) RNA needs reverse-transcription which is costly and RNA could easily be degraded before reverse-transcription, impairing amplification and sequencing quality. On the other hand, unlike other studies which used PBMCs, this study used whole blood preserved in 20% EG and stored at -20°C, followed by DNA extraction subjected to direct amplification and sequencing shows the durability and long term stability of whole blood proviral DNA and thus using of proviral DNA directly from whole blood as a template for determining transmitted drug resistance is less expensive. However, there was difference between the RNA and proviral DNA in drug resistance associated mutations for NRTIs (0 vs 3 samples) which could represent archival genetic resistance which may be transmitted or re-emerge with treatment [14].

The inconsistencies between plasma viral RNA and peripheral blood mononuclear cell proviral DNA in HIV-1 drug resistant strains have been reported from treatment naive individuals ranging from the detection of significantly lower [6, 8] or higher [9, 11] mutations in proviral DNA compared to historic viral RNA. Although, the clinical relevance of transmitted drug resistance mutation in proviral DNA among these treatment naive patients is not defined in the current study, they may not affect the clinical out-comes of ART in short period of time [26]. However, whether these transmitted drug resistance mutation in proviral DNA will be definite risk factors for virologic failure and therefore limiting future treatment options in the course of infection with HAART needs additional investigation. Indeed, it has been shown that the long term persistence of archived drug resistant HIV-1 proviral DNA could undermine the capability of targeted treatment(s) and represents the potential resistance pattern in future [3, 27].

The observed lower abundance of TDR in viral RNA than proviral DNA (14.6% vs 22%) could be conceivably a result of the reversion over time of HIV-1 quasispecies resistant to HAART [28] being archived in proviral DNA [6, 9, 11]. The occurrence of hypermutation in 3 out of 5 sequence of the reverse transcriptase region of the proviral DNA is consistent with recent studies [29].

Four out of the 41 paired samples from both compartments did not show a tight proximity relation to each other suggesting that circulating strains produced in the plasma compartment could arise from sources other than circulating infected leukocytes [14, 30]. Most of the studies on the comparison of HIV-1 drug resistance in cell-free and cell-containing compartments were undertaken in HAART treated subjects [10, 14, 30–33]. The available few data among treatment naive patients [6, 8, 9, 11] were exclusively conducted in HIV-1B isolates. To the best of our knowledge this is the first report among HIV-1C isolates which compares the profile of transmitted drug resistance mutation from paired RNA and proviral DNA templates. The 22.0% of TDR to NNRTIs matches well with earlier observations where NNRTI associated drug resistance mutations were found more frequently than mutations against other ART classes both in HIV-1B [34] and non B subtypes [35, 36]. The profiles of TDR mutations between viral RNA and proviral DNA in the present study are variable in such a way that TDRs mutations conferring resistance to RTIs and PIs were identified more frequently in proviral DNA than viral RNA consistent with previous studies among treatment naive patients [6, 8, 37]. In contrast to these findings, several other studies showed comparable prevalence of TDRs from

### Table 4. Occurrence of polymorphisms at drug resistance sites.

| Antiretroviral drug class | PI | NRTI | NNRTI | Sum  |
|--------------------------|----|------|-------|------|
| Viral RNA                | 1  | 2    | 4     | 7    |
| Proviral DNA             | 2  | 3    | 5     | 10   |

[https://doi.org/10.1371/journal.pone.0205119.t004](https://doi.org/10.1371/journal.pone.0205119.t004)
RNA and proviral DNA among treatment naïve patients [38, 39] and ART experienced and failing patients with history of TDR [10, 11, 27].

Limitations
The data has an obvious limitations including small sample size with few detected drug resistance mutation. Although there is technical improvements in the amplification of drug resistance genome using direct whole blood as a template, the technical improvement over sequencing is limited. It would have been interesting to evaluate the use of more sensitive sequencing approaches such as Next Generation Sequencing (NGS) that might partially explain the observed differences between viral DNA and plasma RNA. Thus, the observed small mutation might be due to the low sensitivity nature of the Sanger sequencing approach. Furthermore, as the nature the study was cross sectional, the clinical importance of the mutations observed only in proviral DNA in terms of being risk factors for virologic failure and whether limits future treatment options is not addressed. Nevertheless, with all these limitation we concluded the points below (Conclusions).

Conclusion
In summary, as sequencing of HIV-1 proviral DNA which is extracted directly from stored whole blood detects all signature mutations observed in RNA and is less expensive and technically easier to perform compared to RNA, determining TDR using the WHO drug resistance surveillance mutation list from proviral DNA could be an alternative approaches especially in resource limited countries. However, the clinical importance of transmitted drug resistance mutations observed only in proviral DNA in terms of being risk factors for virologic failure

| Location | PI mutations | Location | NRTI mutations | Location | NNRTI mutations |
|----------|--------------|----------|----------------|----------|-----------------|
| PR       | Viral RNA    | Pro viral DNA | RT         | Viral RNA | Pro viral DNA | RT | Viral RNA | Pro viral DNA |
| L23      | -            | -        | M41         | 1(I)     | 1(I)           | A98 | 7(S)     | 8(S)       |
| L24      | -            | -        | A62         | -        | -             | L100| -        | -          |
| D30      | -            | -        | K65         | -        | -             | K101| 1(R)     | 1(R)       |
| V32      | -            | -        | D67         | -        | -             | K103| -        | -          |
| L33      | -            | -        | T69         | -        | 1(S)          | V106| -        | -          |
| M46      | -            | -        | K70         | -        | -             | V108| -        | -          |
| I47      | -            | -        | L74         | -        | -             | V179| 2(I)     | 3(I)       |
| G48      | -            | 2(R)     | V75         | -        | -             | Y181| 1(F)     | -          |
| I50      | -            | -        | F77         | -        | -             | Y188| -        | -          |
| F53      | -            | -        | Y115        | -        | -             | G190| -        | 2(R)       |
| I54      | -            | -        | F116        | -        | -             | P225| -        | -          |
| G73      | -            | -        | V118        | 1(I)     | 1(I)          | F227| -        | -          |
| L76      | -            | -        | Q151        | -        | -             | M230| -        | -          |
| V82      | 5(I)         | 5(I)     | M184        | -        | -             | E138| -        | -          |
| I84      | -            | -        | L210        | -        | -             | P236| -        | 1(PT)      |
| N88      | -            | -        | T215        | -        | -             | -   | -        | -          |
| L90      | -            | -        | K219        | -        | -             | -   | -        | -          |

PR-protease; RT-reverse transcriptase; NRTI-nucleoside reverse transcriptase inhibitor; NNRTI- non-NRTI; (-) no polymorphisms detected; (*)-number of mutation (mutant amino acid)

https://doi.org/10.1371/journal.pone.0205119.t005
and limits future treatment options in future needs additional investigation using more sensitive sequencing approaches such as Next Generation Sequencing (NGS).

Acknowledgments
We thank Dr. Ute Brinckmann and Ms Sandra Bergs from the Institute of Virology for their excellent technical support and our appreciation also goes to all study participants.

Author Contributions
Conceptualization: Kahsay Huruy, Andargachew Mulu, Uwe Gerd Liebert, Maier Melanie.

Formal analysis: Kahsay Huruy, Andargachew Mulu, Uwe Gerd Liebert, Maier Melanie.

Funding acquisition: Maier Melanie.

Investigation: Kahsay Huruy, Andargachew Mulu, Maier Melanie.

Methodology: Kahsay Huruy, Andargachew Mulu, Uwe Gerd Liebert, Maier Melanie.

Supervision: Andargachew Mulu, Uwe Gerd Liebert, Maier Melanie.

Validation: Andargachew Mulu, Uwe Gerd Liebert, Maier Melanie.

Writing – original draft: Kahsay Huruy.

Writing – review & editing: Andargachew Mulu, Uwe Gerd Liebert, Maier Melanie.

References
1. Imaz A, Falco V, Ribera E. Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice. AIDS Rev 2011: 13(3):180–93. PMID: 21799536

2. Frentz D, Boucher CAB, van de Vijver DAMC. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012: 14(1):17–27. PMID: 22297501

3. Wainberg MA, Brenner BG. Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs. Viruses 2011 1: 2(11):2493–508.

4. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 2008: 6(5):388–400. PMID: 18655549

5. Turriziani O, Andreoni M, Antonelli G. Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection. Clin Microbiol Infect 2010: 16(10):1518–24. https://doi.org/10.1111/j.1469-0691.2010.03329.x PMID: 20673280

6. Bon I, Gibelli D, Borden M, Alessandrini F, Vitone F, Schiavone P et al. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol 2007: 38 (4):313–20. https://doi.org/10.1016/j.jcv.2006.12.018 PMID: 17306618

7. d’Ettorre G, Zaffiri L, Ceccarelli G, Mastroianni CM, Vullo V. The role of HIV-DNA testing in clinical practice. New Microbiol 2010: 33(1):1–11. PMID: 20402409

8. Kabamba-Mukadi B, Duquenne A, Henriaux P, Musuamba F, Ruelle J, Yombi J et al. HIV-1 proviral resistance mutations: usefulness in clinical practice. HIV Med 2010: 11(8):483–92. https://doi.org/10.1111/j.1468-1293.2009.00814.x PMID: 20163482

9. Parisi SG, Boldrin C, Cruciani M, Nicolini G, Cerbaro I, Manfrin V et al. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients. J Clin Microbiol 2007: 45(6):1783–8. https://doi.org/10.1128/JCM.00056-07 PMID: 17442799

10. Turriziani O, Bucci M, Stano A, Scagnolari C, Bellomi F, Fimiani C et al. Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals. J Acquir Immune Defic Syndr 2007: 44(5):518–24. https://doi.org/10.1097/QAI.0b013e3180315515 PMID: 17224845

11. Vicenti I, Razzolini F, Saladini F, Romano L, Zazzi M. Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects. Clin Infect Dis 2007: 44(12):1657–61. https://doi.org/10.1086/518287 PMID: 17516412

12. Lee GQ, Swenson LC, Poon AFY, Martin JN, Hatano H, Deeks SG et al. Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454
“deep” sequencing. PLoS One 2012: 7(9):e46181. https://doi.org/10.1371/journal.pone.0046181 PMID: 23049972

13. Derache A, Shin H-S, Balamane M, White E, Israelski D, Klausner JD, et al. HIV Drug Resistance Mutations in Proviral DNA from a Community Treatment Program. PLoS ONE 2015: 10(1): e0117430. https://doi.org/10.1371/journal.pone.0117430 PMID: 25635815

14. Banks L, Gholamin S, White E, Zijenah L, Katzenstein DA. Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1. J AIDS Clin Res 2012: 3(2):141–7. PMID: 23019537

15. Demetriou VL, van de Vijver DAMC, Kousiappa I, Balotta C, Clotet B, et al. Cellular HIV-1 DNA Levels in Drug Sensitive Strains Are Equivalent to Those in Drug Resistant Strains in Newly-Diagnosed Patients in Europe. PLoS ONE 2010: 5(6): e10976. https://doi.org/10.1371/journal.pone.010976 PMID: 20544014

16. Kassu A, Fujino M, Matsuda M, Nishizawa M, Ota F, Sugiuwa W. Molecular epidemiology of HIV type 1 in treatment-naive patients in north Ethiopia. AIDS Res Hum Retroviruses 2007: 23(4):564–8. https://doi.org/10.1089/aid.2006.0270 PMID: 17451346

17. Mulu A, Lange T, Liebert UG, Maier M. Clade homogeneity and Pol gene polymorphisms in chronically HIV-1 infected antiretroviral treatment naive patients after the roll out of ART in Ethiopia. BMC Infect Dis 2014: 14(1):158.

18. Abegaz WE, Grossman Z, Wolday D, Ram D, Kaplan J, Sibide K et al. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. AntivirTher 13 Suppl 2008: 2:89–94.

19. Abdissa A, Yilma D, Fonager J, Audelin AM, Christensen LH, Olsen MF et al. Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. BMC Infect Dis 2014: 14:181 https://doi.org/10.1186/1471-2334-14-181 PMID: 24708645

20. Huruy K, Maier M, Mulu A, Liebert UG. Limited increase in primary HIV-1C drug resistance mutations in treatment naive individuals in Ethiopia.J Med Virol 2015: 87(6):978–84. https://doi.org/10.1002/jmv.24110 Epub 2015 Feb PMID: 25649964

21. Mulu A, Maier M, Liebert UG. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study. PLoS One 2015: 10(10): e0141318. https://doi.org/10.1371/journal.pone.0141318 PMID: 26512902

22. Leal-Klevezas DS, Martinez-Vazquez IO, Cuevas-Hernandez B, Martinez-Soriano JP Antifreeze solution improves DNA recovery by preserving the integrity of pathogen-infected blood and other tissues. Clin Diagn Lab Immunol 2000: 7(6):945–6.

23. Casabianca A, Gori C, Orlandi C, Forbici F, Federico Perno C, Magnani M. Fast and sensitive quantitative detection of HIV DNA in whole blood leucocytes by SYBR green I real-time PCR assay. Mol Cell Probes 2007: 21(5–6):368–78. https://doi.org/10.1016/j.mcp.2007.05.005 PMID: 17629450

24. Wensing AM, Calvez V, Günthard HF, Johnson VA, Paredes R, Pillay D, et al. Update of the drug resistance mutations in HIV-1: international AIDS society-USA. Top Antivir Med 2017: 2017; 24(4): [Epub ahead of print]

25. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011: 28(10):2731–9. https://doi.org/10.1093/molbev/msr121 PMID: 21546353

26. Bansode V, McCormack GP, Crampin AC, Ngwira B, Shrestha RK, French N et al. Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra-deep pyrosequencing. BMC Infect Dis 2013: 13:52. https://doi.org/10.1186/1471-2334-13-52 PMID: 23363532

27. Noe A, Plum J, Verhofstede C. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother 2005: 55(4):410–2. https://doi.org/10.1093/jac/dki036 PMID: 15728140

28. Yanik EL, Napravnik S, Hunt CB, Dennis A, Quinlivan EB, Sebastian J et al. (2012) Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr 2012: 61(2):258–62. https://doi.org/10.1097/QAI.0b013e3182618f05 PMID: 22692092

29. Fourati S, Malet I, Lambert S, Soulie C, Wirden M, et al. E138K and M184I mutations in HIV-1 reverse-transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. AIDS 2012: 26(13):1619–24. PMID: 22695298

30. Chew CB, Potter SJ, Wang B, Wang YM, Shaw CO, Dwyer DE et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J ClinVirol 2005: 33(3):206–18.
31. Sanabani SS, Pessoa R, Soares de Oliveira AC, Martinez VP, Giret MTM, de Menezes Succ RC et al. Variability of HIV-1 genomes among children and adolescents from Sao Paulo, Brazil. PLoS One 2013: 8(5):e62552. https://doi.org/10.1371/journal.pone.0062552 PMID: 23667488

32. Saracino A, Gianotti N, Marangi M, Bibelli DC, Galli A, Punzi G et al. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART. J Med Virol 2008: 80(10):1695–706. https://doi.org/10.1002/jmv.21261 PMID: 18712823

33. Venturi G, Romano L, Carli T, Corsi P, Pippi L, Valensin PE et al. Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy. Antivir Ther 2002: 7(4):245–50. PMID: 12553478

34. Yebra G, de Mulder M, del Romero J, Rodriguez C, Holguin A. HIV-1 non-B subtypes: High transmitted NNRTI-resistance in Spain and impaired genotypic resistance interpretation due to variability. Antiviral Res 2010: 85(2):409–17. https://doi.org/10.1016/j.antiviral.2009.11.010 PMID: 20004217

35. Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006: 41(4):439–46. https://doi.org/10.1097/01.qai.0000219290.49152.6a PMID: 16652051

36. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011: 11(10):750–9. https://doi.org/10.1016/S1473-3099(11)70149-9 PMID: 21802367

37. Geretti AM, Conibear T, Hill A, Johnson JA, Tambuyzer L, Thys K et al. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz. J Antimicrob Chemother 2014: 69(4):1090–7. https://doi.org/10.1093/jac/dkt474 PMID: 24284781

38. Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard J, Galimand J et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006: 20(2):159–70. https://doi.org/10.1097/01.aids.0000199820.47703.a0 PMID: 16511408

39. Wang YM, Dyer WB, Workman C, Wang B, Peng NK, Lachireddy K et al. Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART. Curr HIV Res 2007: 5(2):235–50. PMID: 17346137